ネクセラファーマの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/04/26 | 1,261 | 1,273 | 1,251 | 1,267 | +14 | +1.1% | 392,400 |
| 2022/04/25 | 1,240 | 1,268 | 1,238 | 1,253 | -4 | -0.3% | 621,700 |
| 2022/04/22 | 1,265 | 1,271 | 1,247 | 1,257 | -22 | -1.7% | 654,300 |
| 2022/04/21 | 1,267 | 1,287 | 1,263 | 1,279 | -4 | -0.3% | 695,500 |
| 2022/04/20 | 1,321 | 1,321 | 1,282 | 1,283 | -30 | -2.3% | 777,500 |
| 2022/04/19 | 1,329 | 1,348 | 1,311 | 1,313 | -21 | -1.6% | 580,800 |
| 2022/04/18 | 1,344 | 1,354 | 1,322 | 1,334 | -26 | -1.9% | 459,200 |
| 2022/04/15 | 1,368 | 1,370 | 1,348 | 1,360 | -32 | -2.3% | 573,800 |
| 2022/04/14 | 1,382 | 1,404 | 1,374 | 1,392 | +4 | +0.3% | 427,900 |
| 2022/04/13 | 1,362 | 1,391 | 1,361 | 1,388 | +22 | +1.6% | 544,100 |
| 2022/04/12 | 1,391 | 1,394 | 1,363 | 1,366 | -24 | -1.7% | 425,500 |
| 2022/04/11 | 1,414 | 1,419 | 1,377 | 1,390 | -34 | -2.4% | 507,500 |
| 2022/04/08 | 1,437 | 1,438 | 1,413 | 1,424 | -3 | -0.2% | 344,500 |
| 2022/04/07 | 1,397 | 1,440 | 1,391 | 1,427 | +35 | +2.5% | 778,800 |
| 2022/04/06 | 1,427 | 1,427 | 1,384 | 1,392 | -71 | -4.9% | 1,068,300 |
| 2022/04/05 | 1,467 | 1,469 | 1,423 | 1,463 | +23 | +1.6% | 667,200 |
| 2022/04/04 | 1,420 | 1,453 | 1,407 | 1,440 | +37 | +2.6% | 603,300 |
| 2022/04/01 | 1,410 | 1,410 | 1,385 | 1,403 | -12 | -0.8% | 496,100 |
| 2022/03/31 | 1,446 | 1,448 | 1,404 | 1,415 | -33 | -2.3% | 724,900 |
| 2022/03/30 | 1,470 | 1,472 | 1,433 | 1,448 | -6 | -0.4% | 802,300 |
| 2022/03/29 | 1,453 | 1,469 | 1,437 | 1,454 | +14 | +1% | 558,000 |
| 2022/03/28 | 1,487 | 1,487 | 1,426 | 1,440 | -49 | -3.3% | 872,000 |
| 2022/03/25 | 1,483 | 1,494 | 1,449 | 1,489 | +20 | +1.4% | 746,400 |
| 2022/03/24 | 1,454 | 1,472 | 1,434 | 1,469 | +7 | +0.5% | 520,200 |
| 2022/03/23 | 1,483 | 1,492 | 1,447 | 1,462 | -2 | -0.1% | 917,400 |
| 2022/03/22 | 1,494 | 1,494 | 1,456 | 1,464 | -26 | -1.7% | 502,400 |
| 2022/03/18 | 1,476 | 1,520 | 1,470 | 1,490 | +19 | +1.3% | 1,026,300 |
| 2022/03/17 | 1,476 | 1,477 | 1,439 | 1,471 | +25 | +1.7% | 891,800 |
| 2022/03/16 | 1,402 | 1,453 | 1,401 | 1,446 | +74 | +5.4% | 934,600 |
| 2022/03/15 | 1,363 | 1,388 | 1,342 | 1,372 | +11 | +0.8% | 826,700 |
| 2022/03/14 | 1,365 | 1,395 | 1,340 | 1,361 | -11 | -0.8% | 637,200 |
| 2022/03/11 | 1,392 | 1,396 | 1,347 | 1,372 | -19 | -1.4% | 636,800 |
| 2022/03/10 | 1,387 | 1,398 | 1,369 | 1,391 | +49 | +3.7% | 728,100 |
| 2022/03/09 | 1,350 | 1,360 | 1,301 | 1,342 | +7 | +0.5% | 978,500 |
| 2022/03/08 | 1,311 | 1,361 | 1,300 | 1,335 | +15 | +1.1% | 1,338,600 |
| 2022/03/07 | 1,325 | 1,355 | 1,301 | 1,320 | -44 | -3.2% | 1,154,200 |
| 2022/03/04 | 1,430 | 1,438 | 1,342 | 1,364 | -69 | -4.8% | 1,412,700 |
| 2022/03/03 | 1,460 | 1,473 | 1,412 | 1,433 | -7 | -0.5% | 983,000 |
| 2022/03/02 | 1,427 | 1,469 | 1,416 | 1,440 | +9 | +0.6% | 1,406,000 |
| 2022/03/01 | 1,414 | 1,439 | 1,384 | 1,431 | +12 | +0.8% | 1,516,500 |
| 2022/02/28 | 1,399 | 1,433 | 1,380 | 1,419 | +5 | +0.4% | 958,600 |
| 2022/02/25 | 1,375 | 1,421 | 1,355 | 1,414 | +81 | +6.1% | 1,497,600 |
| 2022/02/24 | 1,407 | 1,414 | 1,311 | 1,333 | -77 | -5.5% | 2,403,900 |
| 2022/02/22 | 1,381 | 1,451 | 1,380 | 1,410 | +5 | +0.4% | 1,300,500 |
| 2022/02/21 | 1,420 | 1,424 | 1,377 | 1,405 | -50 | -3.4% | 1,351,800 |
| 2022/02/18 | 1,409 | 1,461 | 1,403 | 1,455 | +16 | +1.1% | 1,148,100 |
| 2022/02/17 | 1,488 | 1,493 | 1,424 | 1,439 | -38 | -2.6% | 1,382,400 |
| 2022/02/16 | 1,510 | 1,512 | 1,466 | 1,477 | -3 | -0.2% | 1,155,300 |
| 2022/02/15 | 1,470 | 1,519 | 1,464 | 1,480 | ±0 | ±0% | 1,049,100 |
| 2022/02/14 | 1,432 | 1,480 | 1,375 | 1,480 | -52 | -3.4% | 1,868,200 |
601～
650
件表示中 / 4944件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ネクセラファーマ | 125,100円 | +197.7% | - | 0.00% | 51.12倍 | 1.63倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ゼリア新薬 | 233,800円 | +9.6% | +17.5% | 1.97% | 13.21倍 | 1.29倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| 鳥居薬 | 393,500円 | +11.1% | +20.6% | 3.05% | 23.05倍 | 0.92倍 |
|
ＪＴ傘下。柱の抗ＨＩＶ薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
| 杏林製薬 | 153,100円 | +3.2% | +4.5% | 3.40% | 17.59倍 | 0.67倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 栄研化 | 246,000円 | +7.6% | +57.5% | 2.15% | 19.02倍 | 1.87倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
